Toxicity Assessment of Precision-Engineered Allo-HSCT


Safety and toxicity data from a clinical trial investigating a novel, precision-engineered allo-HSCT conditioning regimen for older patients with high-risk blood cancers.

This is a video synopsis/summary of a Peer Exchange featuring Miguel-Angel Perales, MD; Nelli Bejanyan, MD; Amandeep Salhotra, MD; and Arpita Gandhi, MD, MS.

The panel discusses the toxicities observed with the Orca T-cell therapy (Orca-T) graft, a graft manipulation approach that involves adding regulatory T-cells and conventional T-cells (Tcons) to a CD34-selected graft. Due to tacrolimus alone, without methotrexate, patients experience minimal toxicities, faster engraftment, and earlier hospital discharge. The most notable change is the minimal incidence of mucositis, with only 2 patients (1 younger and 1 older) experiencing grade 3 or higher mucositis in the study presented.

The Orca-T platform is currently being evaluated in myeloablative transplants, and the next step is to assess its efficacy in reduced-intensity transplants. An ongoing study presented at the 2023 American Hematology Society Annual Meeting & Expo addresses this aspect. The panel emphasizes that the combination of conditioning regimen, methotrexate, and calcineurin inhibitor contributes to toxicity, making the age of 55 years a common cutoff for ablative vs reduced-intensity transplants.

Patients with hematologic malignancies, such as acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome, who have a matched donor and are eligible for myeloablative conditioning are considered for the Orca-T graft. Studies are also exploring the use of the Orca-T graft with reduced-intensity regimens and in mismatched and haploidentical donor settings, highlighting the adaptability of this platform. The addition of a defined population of Tcons promotes engraftment, even in mismatched or reduced-intensity settings.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
Jorge J. Castillo, MD,
Video 10 - "SELECT Trial & DECISION Trial Outcomes and Lessons Learned"
Video 9 - "Identifying RAI-Refractory Disease: A Key Aspect of DTC Management"
Video 18 - "Future Perspectives and Unmet Needs in Renal Cell Carcinoma"
Video 17 - "Nivolumab Plus Cabozantinib in Non–Clear Cell RCC"
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Alessandra Ferrajoli, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center